AzTrials
AzTrials

Excessive Daytime SleepinessPhase 2NCT01006122

A Study Of A Novel Compound For Excessive Daytime Sleepiness Associated With Narcolepsy

A Phase 2 study testing PF-03654746 in people with Excessive Daytime Sleepiness and Narcolepsy, run by Pfizer at 21 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Histaminergic agents are known to be involved with the sleep/wake cycle. This compound is a histaminergic agent which therefore may improve alertness and awakeness in patients with excessive daytime sleepiness (EDS) associated with narcolepsy. Read more about this study

Who is it for?
Ages 18 to 55 years
Conditions the study is for
Excessive Daytime Sleepiness, Narcolepsy
What is being tested?
PF-03654746
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
95 participants
Where
21 sitesUnited States
Study dates
Nov 2009to Nov 2010
Phase
Phase 2
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 55 years
  • All sexes
  • No healthy volunteers
  • Adult

Who may be able to join

  • ISDC diagnosis of narcolepsy
  • Excessive Daytime Sleepiness in association with a diagnosis of narcolepsy
  • An MWT (Maintenance of Wakefulness Test) average sleep latency of under 15 minutes at Baseline

Who cannot join

  • No other diagnosed sleep disorders (e.g., sleep apnea)
  • Major medical disorders
  • Major psychiatric disorders

Trial locations and contacts

21 sites in 1 country.

21 sites in 1 country

United States21 sites
  • Pfizer Investigational Site

    Atlanta, Georgia, 30342

  • Pfizer Investigational Site

    Austin, Texas, 78731

  • Pfizer Investigational Site

    Brandon, Florida, 33511

  • Pfizer Investigational Site

    Columbia, South Carolina, 29201

  • Pfizer Investigational Site

    Crestview Hills, Kentucky, 41017

  • Pfizer Investigational Site

    Dublin, Ohio, 43017

  • Pfizer Investigational Site

    Durham, North Carolina, 27710

  • Pfizer Investigational Site

    Hattiesburg, Mississippi, 39401

  • Pfizer Investigational Site

    Hattiesburg, Mississippi, 39402

  • Pfizer Investigational Site

    Houston, Texas, 77063

  • Pfizer Investigational Site

    Los Angeles, California, 90048

  • Pfizer Investigational Site

    Louisville, Kentucky, 40217

  • Pfizer Investigational Site

    Macon, Georgia, 31201

  • Pfizer Investigational Site

    Orange, California, 92868

  • Pfizer Investigational Site

    Philadelphia, Pennsylvania, 19114

  • Pfizer Investigational Site

    Philadelphia, Pennsylvania, 19139

  • Pfizer Investigational Site

    Phoenix, Arizona, 85006

  • Pfizer Investigational Site

    Phoenix, Arizona, 85051

  • Pfizer Investigational Site

    St. Petersburg, Florida, 33707

  • Pfizer Investigational Site

    Tucson, Arizona, 85712

  • Pfizer Investigational Site

    Vernon Hills, Illinois, 60061

Other trials in United States

About this study

Official title: A Randomized Phase 2, Double Blind, Placebo-Controlled, Multi-Center Crossover Study Of PF-03654746 As A Daily Treatment For Excessive Daytime Sleepiness (EDS) Associated With Narcolepsy

Histaminergic agents are known to be involved with the sleep/wake cycle. This compound is a histaminergic agent which therefore may improve alertness and awakeness in patients with excessive daytime sleepiness (EDS) associated with narcolepsy. Significant improvement in EDS when treated with this compound compared to placebo in patients with narcolepsy is hypothesized.

Being tested
Placebo, PF-03654746
Keywords
Randomized, double-blind, placebo-controlled, crossover study of PF-03654746 in Excessive Daytime Sleepiness associated with Narcolepsy
Medical subject headings
Disorders of Excessive Somnolence, Narcolepsy

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • PlaceboDrug

    Patients receiving placebo will undergo the same procedures as those receiving active treatment. Each patient will receive matching placebo tablets in a fixed dose escalation schedule beginning at 0.25 mg QD for 5 days; then up to 0.50 mg QD for another 5 days; and up to 1.0 mg QD for an additional 5 days. At the end of this fixed titration schedule, the patient will either stay at 1.0 mg; decrease to 0.5 mg or increase to 2.0 mg based upon the clinicians judgment regarding efficacy and side effects at the 1.0 dose level. The patient will then remain at the determined dose for a 3 week stable dosing period, with a 7 (-2/+ 9) day wash out and then crossover to repeat the same sequence for the second arm of the study.

  • PF-03654746Drug

    Each patient will receive PF-03654746 tablets in a fixed dose titration schedule beginning at 0.25 mg QD for 5 days; then up to 0.50 mg QD for another 5 days; and up to 1.0 mg QD for an additional 5 days. At the end of this fixed titration schedule, the patient will either stay at the 1.0 mg dose; decrease to 0.50 mg or increase to 2.0 mg based upon the clinician's judgement regarding efficacy and side effects at the 1.0 mg dose. The patient will remain at the determined dose for a 3 week stable dosing period.

Study groups in NCT01006122
Study groupRoleWhat they receive
PlaceboPlacebo comparatorNot described
Receives: Drug: Placebo
PF-03654746Active comparatorAt the end of the second arm of the study, the patient will have completed the study and have a 7-10 day follow-up visit.
Receives: Drug: PF-03654746

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change From Baseline in Maintenance of Wakefulness Test (MWT) Score at Day 21 of Stable Dosing Phase

    MWT measured ability of participant to remain awake. Participants were instructed to try and remain awake during series of six 20-minute periods in a semi-recumbent position in dark room. Each period was terminated immediately after sleep onset or at end of 20 minutes if no sleep occurred. Poorest outcome was 0 minute the best was 20 minutes.

    Measured: Baseline, Day 21 of stable dosing phase

Secondary outcomes (11)
  1. Change From Baseline in Epworth Sleepiness Scale (ESS) Total Score at Day 5, 10, 15, 20 of Titration Phase and Day 7, 14, 21 of Stable Dosing Phase

    ESS is a simple, self-administered questionnaire which provides a measurement of the participant's general level of daytime sleepiness. The participant rates the chance that he/she would fall asleep when in 8 different situations (e.g. sitting and reading, talking to someone, etc.) commonly encountered in daily life on a scale of 0 (no daytime sleep) to 3 (maximum daytime sleep). Total score was the sum of 8 situations ranges from 0 to 24 with a higher score indicating greater daytime sleepiness.

    Measured: Baseline, Day 5, 10, 15, 20 of titration phase; Day 7, 14, 21 of stable dosing phase

  2. Change From Baseline in Brief Fatigue Inventory (BFI) Global Score at Day 5, 10, 15, 20 of Titration Phase and Day 7, 14, 21 of Stable Dosing Phase

    BFI is a subjective-completed tool for the assessment of the impact of fatigue on daily functioning. There are 3 questions that pertain specifically to level of fatigue and 6 questions regarding general activity level, mood and quality of life, all are answered on an 11-point scale, with "0" being "No fatigue at all" to "10" being "As bad as you can imagine". The global score is calculated by taking the sum of all 9 rating scales for a minimum score of 0 and a maximum score of 90. Higher global scores are associated with more severe fatigue.

    Measured: Baseline, Day 5, 10, 15, 20 of titration phase; Day 7, 14, 21 of stable dosing phase

  3. Change From Baseline in Cataplexy Episodes at Day 7, 14, 21 of Stable Dosing Phase

    Cataplexy is a medical condition in which a person suffers sudden physical collapse though remaining conscious. Cataplexy episodes is number of counts the participant had cataplexy.

    Measured: Baseline, Day 7, 14, 21 of stable dosing phase

  4. Change From Baseline in 36-Item Short Form Health Survey (SF-36) at Day 21 of Stable Dosing Phase

    SF-36 is a standardized survey evaluating 8 aspects of functional health and well-being: physical functioning (PF), role physical (RP), bodily pain (BP), general health (GH), vitality, social functioning (SF), role emotional (RE) and mental health (MH). The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).

    Measured: Baseline, Day 21 of stable dosing phase

  5. Clinical Global Impression of Improvement (CGI-I) Scale Score

    CGI-I: 7-point clinician rated scale ranging from 1 (very much improved) to 7 (very much worse). Clinician responded to a question: "Compared to your subject's condition at the beginning of treatment, how much has your subject changed?". Improvement was compared to baseline and was defined as a score of 1 (very much improved), 2 (much improved), or 3 (minimally improved) on the scale. Higher score = more affected.

    Measured: Day 5, 10, 15, 20 of titration phase; Day 7, 14, 21 of stable dosing phase

  6. Computer Based Objective Cognition Testing (CogState) Groton Maze Learning Task (GMLT)

    GMLT: a cognitive test which assessed executive function. Participant was shown a 10 multiplied by 10 grid of tiles on a computer touch screen. A 28-step pathway was hidden among 100 possible locations. The participant was instructed to move 1 step from the start location and then continue 1 tile at a time, toward the end to find the pathway. The outcome measure was total number of errors made in attempting to learn the same hidden pathway on 5 consecutive trials at a single session. Score ranges from 0 to infinity. Lower scores meant a better performance.

    Measured: Baseline, Day 5, 10, 15, 20 of titration phase; Day 21 of stable dosing phase

  7. Computer Based Objective Cognition Testing (CogState) Detection Speed

    Detection speed: a cognitive test which assessed psychomotor function. A playing card was presented face up in the center of the screen. As soon as this happened, the participant was to press the 'Yes' key. The outcome measure was speed of performance; mean of the log10 transformed reaction time for correct responses [measured in log10 milliseconds (msec)]. Scores ranges from 2 (best) to 3.3 (worst). Lower scores meant a better performance.

    Measured: Baseline, Day 5, 10, 15, 20 of titration phase; Day 21 of stable dosing phase

  8. Computer Based Objective Cognition Testing (CogState) Identification Speed

    Identification speed: a cognitive test which assessed visual attention. A playing card was presented face up in the center of the screen. As soon as this happened, the participant had to decide whether the card was red or not. The outcome measure was speed of performance; mean of the log10 transformed reaction time for correct responses (measured in log10 msec). Score ranges from 2 (best) to 3.3 (worst). Lower scores meant a better performance.

    Measured: Baseline, Day 5, 10, 15, 20 of titration phase; Day 21 of stable dosing phase

  9. Computer Based Objective Cognition Testing (CogState) One Card Learning

    One card learning: a cognitive test which assessed visual learning. Participants were to remember which cards were previously shown in a task. The outcome measure was accuracy of performance; arcsine transformation of the square root of the proportion of correct responses. Score ranges from 0 (worse) to 1.57 (best). Higher scores meant a better performance.

    Measured: Baseline, Day 5, 10, 15, 20 of titration phase; Day 21 of stable dosing phase

  10. Computer Based Objective Cognition Testing (CogState) Continuous Paired Associate Learning (CPAL)

    CPAL: a cognitive test which assessed visual episodic learning. Participant was to learn and remember picture locations on the screen and was to tap the target on the central location to begin. As each picture was revealed, the participant was to remember where the picture was located and tap that location. The outcome measure was the number of errors made in correctly placing each of the 4 patterns in their location 4 times. Score ranges from 0 to infinity. Lower scores meant a better performance.

    Measured: Baseline, Day 5, 10, 15, 20 of titration phase; Day 21 of stable dosing phase

  11. Computer Based Objective Cognition Testing (CogState ) Composite Score

    CogState had 5 outcome measures that measured the cognitive constructs. GMLT, detection, identification, one card learning and CPAL. GMLT score range: 0 (best) to infinity (worst), detection and identification score range: 2 (best) to 3.3 (worst); One card learning score range: 0 (worse) to 1.57 (best) and CPAL score range: 0 (best) to infinity (worst). The individual score was standardized at each assessment and was then averaged to yield a composite score; total possible score: minus infinity to plus infinity. Positive composite score=improved performance.

    Measured: Baseline, Day 5, 10, 15, 20 of titration phase; Day 21 of stable dosing phase

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted2 Nov 2009 (estimated)
  2. Study startNov 2009
  3. Primary completionNov 2010
  4. Study completionNov 2010

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Crossover
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
95 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01006122
Sponsor's protocol ID
A8801015
Status last verified
Apr 2014
First submitted
29 Oct 2009
Last updated
9 May 2014
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing PF-03654746 in people with Excessive Daytime Sleepiness and Narcolepsy, run by Pfizer at 21 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 9 May 2014. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 21 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 9 May 2014). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change From Baseline in Maintenance of Wakefulness Test (MWT) Score at Day 21 of Stable Dosing Phase (time frame: Baseline, Day 21 of stable dosing phase). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 May 2014.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in